The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition.

Autor: Anzar I; Oslo Cancer Cluster, NEC OncoImmunity AS, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Malone B; Oslo Cancer Cluster, NEC OncoImmunity AS, Oslo, Norway., Samarakoon P; Oslo Cancer Cluster, NEC OncoImmunity AS, Oslo, Norway., Vardaxis I; Oslo Cancer Cluster, NEC OncoImmunity AS, Oslo, Norway., Simovski B; Oslo Cancer Cluster, NEC OncoImmunity AS, Oslo, Norway., Fontenelle H; Oslo Cancer Cluster, NEC OncoImmunity AS, Oslo, Norway., Meza-Zepeda LA; Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Oslo University Hospital, Oslo, Norway., Stratford R; Oslo Cancer Cluster, NEC OncoImmunity AS, Oslo, Norway., Keung EZ; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Burgess M; Department of Medical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States., Tawbi HA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Myklebost O; Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Clancy T; Oslo Cancer Cluster, NEC OncoImmunity AS, Oslo, Norway.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Sep 20; Vol. 14, pp. 1226445. Date of Electronic Publication: 2023 Sep 20 (Print Publication: 2023).

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.

Autor: Ellingsen EB; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway. espen.ellingsen@ultimovacs.com.; Faculty of Medicine, University of Oslo, Oslo, Norway. espen.ellingsen@ultimovacs.com.; Ultimovacs ASA, Oslo, Norway. espen.ellingsen@ultimovacs.com., Bounova G; ENPICOM B.V., DA 's-Hertogenbosch, Netherlands., Kerzeli I; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden., Anzar I; NEC Oncoimmunity, Oslo, Norway., Simnica D; Department for Internal Medicine IV - Hematology and Oncology, Universitätsklinikum Halle (Saale), Halle, Germany., Aamdal E; Department of Oncology, Oslo University Hospital, Oslo, Norway., Guren T; Department of Oncology, Oslo University Hospital, Oslo, Norway., Clancy T; NEC Oncoimmunity, Oslo, Norway., Mezheyeuski A; HistoOne AB, Uppsala, Sweden., Inderberg EM; Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Mangsbo SM; Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.; Ultimovacs AB, Uppsala, Sweden., Binder M; Department for Internal Medicine IV - Hematology and Oncology, Universitätsklinikum Halle (Saale), Halle, Germany., Hovig E; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway.; Centre for Bioinformatics, University of Oslo, Oslo, Norway., Gaudernack G; Ultimovacs ASA, Oslo, Norway.

Publikováno v: Journal of translational medicine [J Transl Med] 2022 Sep 11; Vol. 20 (1), pp. 419. Date of Electronic Publication: 2022 Sep 11.

Insights into sequence variations underpinning key commercial traits in two tomato landraces

Autor: Tranchida-Lombardo V., Aiese Cigliano R., Anzar I., Landi S., Palombieri S., Colantuono C., Bostan H., Termolino P., Aversano R., Batelli G., Cammareri M., Carputo D., Chiusano M.L., Conicella C., Consiglio M.F., D'Agostino N., De Palma M., Di Matteo A., Grandillo S., Sanseverino W., Tucci M., Grillo S.

Publikováno v: 19th Eucarpia Meeting of the Tomato Working Group, pp. 70–70, Naples, May 2-4, 2018
info:cnr-pdr/source/autori:Tranchida-Lombardo V., Aiese Cigliano R., Anzar I., Landi S., Palombieri S., Colantuono C., Bostan H., Termolino P., Aversano R., Batelli G., Cammareri M., Carputo D., Chiusano M.L., Conicella C., Consiglio M.F., D'Agostino N., De Palma M., Di Matteo A., Grandillo S., Sanseverino W., Tucci M., Grillo S./congresso_nome:19th Eucarpia Meeting of the Tomato Working Group/congresso_luogo:Naples/congresso_data:May 2-4, 2018/anno:2018/pagina_da:70/pagina_a:70/intervallo_pagine:70–70

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::a7fea2835e57e275721cf8602d223338
https://publications.cnr.it/doc/391217

Amelanotic Melanoma—Biochemical and Molecular Induction Pathways.

Autor: Misiąg, Piotr^1,2 (AUTHOR) piotr.misiag@student.umw.edu.pl, Molik, Klaudia^1,2 (AUTHOR) klaudia.molik@student.umw.edu.pl, Kisielewska, Monika^1,2 (AUTHOR) monika.kisielewska@student.umw.edu.pl, Typek, Paulina^1,2 (AUTHOR) paulina.typek@student.umw.edu.pl, Skowron, Izabela^1,2 (AUTHOR) izabela.skowron@student.umw.edu.pl, Karwowska, Anna^1,2 (AUTHOR) anna.karwowska@student.umw.edu.pl, Kuźnicki, Jacek^1,2 (AUTHOR) jacek.kuznicki@student.umw.edu.pl, Wojno, Aleksandra^1,2 (AUTHOR) aleksandra.wojno@student.umw.edu.pl, Ekiert, Marcin³ (AUTHOR) marcin.ekiert@umw.edu.pl, Choromańska, Anna⁴ (AUTHOR) anna.choromanska@umw.edu.pl

Publikováno v: International Journal of Molecular Sciences. Nov2024, Vol. 25 Issue 21, p11502. 26p.

Improved HLA typing of Class I and Class II alleles from next-generation sequencing data.

Autor: Sverchkova A; NEC OncoImmunity AS, Oslo Cancer Cluster, Innovation Park, Oslo, Norway., Anzar I; NEC OncoImmunity AS, Oslo Cancer Cluster, Innovation Park, Oslo, Norway., Stratford R; NEC OncoImmunity AS, Oslo Cancer Cluster, Innovation Park, Oslo, Norway., Clancy T; NEC OncoImmunity AS, Oslo Cancer Cluster, Innovation Park, Oslo, Norway.

Publikováno v: HLA [HLA] 2019 Dec; Vol. 94 (6), pp. 504-513. Date of Electronic Publication: 2019 Oct 08.